Total Payments
$488,762
2024 Payments
$10,395
Companies
2
Transactions
54
Medicare Patients
7,123
Medicare Billing
$394,228
Payment Breakdown by Category
Research$485,150 (99.3%)
Consulting$3,570 (0.7%)
Food & Beverage$41.82 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $485,150 | 44 | 99.3% |
| Consulting Fee | $3,570 | 9 | 0.7% |
| Food and Beverage | $41.82 | 1 | 0.0% |
Payments by Type
Research
$485,150
44 transactions
General
$3,612
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $485,192 | 45 | $0 (2024) |
| Merck Sharp & Dohme LLC | $3,570 | 9 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,395 | 2 | E.R. Squibb & Sons, L.L.C. ($10,395) |
| 2023 | $7,950 | 2 | E.R. Squibb & Sons, L.L.C. ($7,950) |
| 2022 | $1,455 | 2 | E.R. Squibb & Sons, L.L.C. ($1,455) |
| 2021 | $3,570 | 9 | Merck Sharp & Dohme LLC ($3,570) |
| 2019 | $102,875 | 8 | E.R. Squibb & Sons, L.L.C. ($102,875) |
| 2018 | $215,700 | 15 | E.R. Squibb & Sons, L.L.C. ($215,700) |
| 2017 | $146,817 | 16 | E.R. Squibb & Sons, L.L.C. ($146,817) |
All Payment Transactions
54 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/04/2024 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $9,795.00 | Research |
| Study: Ph II MORAb-202 in 2L Platinum Resistant Ovarian Cancer | ||||||
| 01/04/2024 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $600.00 | Research |
| Study: Fuc-GM1 + nivo/chemo vs nivo/chemo in 1L IO Naive SCLC - A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer | ||||||
| 02/08/2023 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $1,755.00 | Research |
| Study: Ph II MORAb-202 in 2L Platinum Resistant Ovarian Cancer | ||||||
| 01/05/2023 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $6,195.00 | Research |
| Study: Fuc-GM1 + nivo/chemo vs nivo/chemo in 1L IO Naive SCLC - A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer | ||||||
| 04/06/2022 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $1,380.00 | Research |
| Study: Fuc-GM1 nivo chemo vs nivo chemo in 1L IO Naive SCLC - A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer | ||||||
| 04/06/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $75.00 | Research |
| Study: Phase III Peri-Adjuvant NSCLC Nivo Mono - A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo fo • Category: Oncology | ||||||
| 12/07/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $480.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $480.00 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,620.00 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $240.00 | General |
| Category: ONCOLOGY | ||||||
| 08/02/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $240.00 | General |
| Category: ONCOLOGY | ||||||
| 07/06/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $240.00 | General |
| Category: ONCOLOGY | ||||||
| 06/08/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $60.00 | General |
| Category: ONCOLOGY | ||||||
| 05/07/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $60.00 | General |
| Category: ONCOLOGY | ||||||
| 03/10/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 01/11/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $28,200.00 | Research |
| Study: An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen Cetuximab CisplatinCarboplatin Fluorouracil as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck SCCHN • Category: Oncology | ||||||
| 01/11/2019 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $26,175.00 | Research |
| Study: A Phase I2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody BMS-986016 Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody Nivolumab, BMS-936558 in Advanced Solid Tumors | ||||||
| 01/11/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $12,800.00 | Research |
| Study: Open-Label, Randomized Trial of Nivolumab BMS-936558 Plus PemetrexedPlatinum or Nivolumab Plus Ipilimumab BMS-734016 vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer NSCLC Subjects With Epidermal Growth Factor Receptor EGFR Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy • Category: Oncology | ||||||
| 01/11/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $12,750.00 | Research |
| Study: Non-Comparative, Open-Label, Multiple Cohort, Phase 12 Study of Nivolumab and Nivolumab Plus Ipilimumab in Subjects With Virus-Positive and Virus-Negative Solid Tumors • Category: Oncology | ||||||
| 01/11/2019 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $11,325.00 | Research |
| Study: A Randomized, Double-Blind Phase 23 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma | ||||||
| 01/11/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $10,500.00 | Research |
| Study: A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck SCCHN • Category: Oncology | ||||||
| 01/11/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $675.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Participants With Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck SCCHN • Category: Oncology | ||||||
| 01/11/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $450.00 | Research |
| Study: Randomized, Open-label, Phase 3 Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Participants With Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant ASCT Advanced Stage Classical Hodgkin Lymphoma CheckMate 812 CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 812 • Category: Oncology | ||||||
| 12/07/2018 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $2,900.00 | Research |
| Study: A Randomized Double Blind Phase 2 3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma | ||||||
| 12/07/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $150.00 | Research |
| Study: A Randomized Double blind Placebo controlled Phase 3 Study of Nivolumab or Nivolumab Plus Cisplatin in Combination With Radiotherapy in Participants With Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and • Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase I 2a Dose Escalation and Cohort Expansion Study of the Safety Tolerability and Efficacy of Anti LAG 3 Monoclonal Antibody BMS 986016 Administered Alone and in Combination With Anti PD 1 Monoclonal Antibody Nivolumab BMS 936558 in Advanced Solid Tu | E.R. Squibb & Sons, L.L.C. | $92,050 | 5 |
| A Phase 1 2 Study of the Combination of Lirilumab Anti KIR Plus Nivolumab Anti PD 1 or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors | E.R. Squibb & Sons, L.L.C. | $87,950 | 5 |
| An Open Label Randomized Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen Cetuximab Cisplatin Carboplatin Fluorouracil as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and | E.R. Squibb & Sons, L.L.C. | $69,750 | 4 |
| A Double Blind Randomized Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck SCCHN | E.R. Squibb & Sons, L.L.C. | $59,150 | 5 |
| An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen Cetuximab CisplatinCarboplatin Fluorouracil as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck SCCHN | E.R. Squibb & Sons, L.L.C. | $28,200 | 1 |
| A Phase I2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody BMS-986016 Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody Nivolumab, BMS-936558 in Advanced Solid Tumors | E.R. Squibb & Sons, L.L.C. | $26,175 | 1 |
| Non Comparative Open Label Multiple Cohort Phase 1 2 Study of Nivolumab and Nivolumab Plus Ipilimumab in Subjects With Virus Positive and Virus Negative Solid Tumors | E.R. Squibb & Sons, L.L.C. | $24,825 | 4 |
| Open Label Randomized Trial of Nivolumab BMS 936558 Plus Pemetrexed Platinum or Nivolumab Plus Ipilimumab BMS 734016 vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non Small Cell Lung Cancer NSCLC Subjects With Epidermal Growth Factor Receptor EGFR | E.R. Squibb & Sons, L.L.C. | $14,900 | 4 |
| Open-Label, Randomized Trial of Nivolumab BMS-936558 Plus PemetrexedPlatinum or Nivolumab Plus Ipilimumab BMS-734016 vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer NSCLC Subjects With Epidermal Growth Factor Receptor EGFR Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy | E.R. Squibb & Sons, L.L.C. | $12,800 | 1 |
| Non-Comparative, Open-Label, Multiple Cohort, Phase 12 Study of Nivolumab and Nivolumab Plus Ipilimumab in Subjects With Virus-Positive and Virus-Negative Solid Tumors | E.R. Squibb & Sons, L.L.C. | $12,750 | 1 |
| Ph II MORAb-202 in 2L Platinum Resistant Ovarian Cancer | E.R. Squibb & Sons, L.L.C. | $11,550 | 2 |
| A Randomized, Double-Blind Phase 23 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma | E.R. Squibb & Sons, L.L.C. | $11,325 | 1 |
| Phase IIIb IV Randomized Double Blinded Study of Nivolumab 3 mg kg in Combination With Ipilimumab 1 mg kg vs Nivolumab 1 mg kg in Combination With Ipilimumab 3 mg kg in Subjects With Previously Untreated Unresectable or Metastatic Melanoma | E.R. Squibb & Sons, L.L.C. | $10,800 | 1 |
| A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck SCCHN | E.R. Squibb & Sons, L.L.C. | $10,500 | 1 |
| Fuc-GM1 + nivo/chemo vs nivo/chemo in 1L IO Naive SCLC - A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer | E.R. Squibb & Sons, L.L.C. | $6,795 | 2 |
| A Randomized Double Blind Phase 2 3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma | E.R. Squibb & Sons, L.L.C. | $2,900 | 1 |
| Fuc-GM1 nivo chemo vs nivo chemo in 1L IO Naive SCLC - A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer | E.R. Squibb & Sons, L.L.C. | $1,380 | 1 |
| A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Participants With Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck SCCHN | E.R. Squibb & Sons, L.L.C. | $675.00 | 1 |
| Randomized, Open-label, Phase 3 Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Participants With Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant ASCT Advanced Stage Classical Hodgkin Lymphoma CheckMate 812 CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 812 | E.R. Squibb & Sons, L.L.C. | $450.00 | 1 |
| A Randomized Double blind Placebo controlled Phase 3 Study of Nivolumab or Nivolumab Plus Cisplatin in Combination With Radiotherapy in Participants With Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and | E.R. Squibb & Sons, L.L.C. | $150.00 | 1 |
| Phase III Peri-Adjuvant NSCLC Nivo Mono - A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo fo | E.R. Squibb & Sons, L.L.C. | $75.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 1,678 | 1,873 | $397,374 | $94,224 |
| 2022 | 8 | 1,822 | 2,048 | $405,204 | $99,419 |
| 2021 | 9 | 2,210 | 2,372 | $434,876 | $114,434 |
| 2020 | 8 | 1,413 | 1,601 | $299,792 | $86,151 |
Total Patients
7,123
Total Services
7,894
Medicare Billing
$394,228
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 74177 | Ct scan of abdomen and pelvis with contrast | Facility | 2023 | 448 | 529 | $119,025 | $33,151 | 27.9% |
| 71260 | Ct scan of chest with contrast | Facility | 2023 | 330 | 406 | $66,584 | $16,062 | 24.1% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 171 | 183 | $41,793 | $11,170 | 26.7% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Facility | 2023 | 154 | 164 | $54,940 | $9,549 | 17.4% |
| 71250 | Ct scan of chest without contrast | Facility | 2023 | 226 | 230 | $36,110 | $8,754 | 24.2% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 134 | 146 | $24,250 | $5,529 | 22.8% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Office | 2023 | 63 | 63 | $21,105 | $3,834 | 18.2% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 97 | 97 | $15,229 | $3,488 | 22.9% |
| 74178 | Ct scan of abdomen and pelvis before and after contrast | Facility | 2023 | 23 | 23 | $5,750 | $1,579 | 27.5% |
| 76377 | 3d radiographic procedure with computerized image postprocessing | Facility | 2023 | 20 | 20 | $10,200 | $590.15 | 5.8% |
| 74160 | Ct scan of abdomen with contrast | Facility | 2023 | 12 | 12 | $2,388 | $518.85 | 21.7% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Facility | 2022 | 414 | 496 | $111,600 | $31,193 | 28.0% |
| 71260 | Ct scan of chest with contrast | Facility | 2022 | 341 | 422 | $69,208 | $16,063 | 23.2% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2022 | 203 | 223 | $50,175 | $13,833 | 27.6% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Facility | 2022 | 159 | 166 | $44,570 | $9,812 | 22.0% |
| 71260 | Ct scan of chest with contrast | Office | 2022 | 180 | 200 | $32,800 | $7,606 | 23.2% |
| 71250 | Ct scan of chest without contrast | Facility | 2022 | 209 | 214 | $33,598 | $7,257 | 21.6% |
| 71250 | Ct scan of chest without contrast | Office | 2022 | 171 | 174 | $27,318 | $5,831 | 21.3% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Office | 2022 | 95 | 97 | $26,255 | $5,681 | 21.6% |
| 74178 | Ct scan of abdomen and pelvis before and after contrast | Facility | 2022 | 14 | 14 | $3,500 | $962.99 | 27.5% |
| 74160 | Ct scan of abdomen with contrast | Facility | 2022 | 13 | 18 | $3,582 | $725.66 | 20.3% |
| 76705 | Limited ultrasound scan of abdomen | Facility | 2022 | 12 | 13 | $1,729 | $267.71 | 15.5% |
| 93971 | Ultrasound study of one arm or leg veins with compression and maneuvers | Facility | 2022 | 11 | 11 | $869.00 | $186.93 | 21.5% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Facility | 2021 | 374 | 424 | $95,400 | $27,918 | 29.3% |
| 71260 | Diagnostic ct scan of chest with contrast | Facility | 2021 | 391 | 448 | $73,472 | $18,367 | 25.0% |
About Dr. Nikhil Ramaiya, MD
Dr. Nikhil Ramaiya, MD is a Diagnostic Radiology healthcare provider based in West Palm Beach, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013996339.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nikhil Ramaiya, MD has received a total of $488,762 in payments from pharmaceutical and medical device companies, with $10,395 received in 2024. These payments were reported across 54 transactions from 2 companies. The most common payment nature is "" ($485,150).
As a Medicare-enrolled provider, Ramaiya has provided services to 7,123 Medicare beneficiaries, totaling 7,894 services with total Medicare billing of $394,228. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Diagnostic Radiology
- Location West Palm Beach, FL
- Active Since 01/13/2006
- Last Updated 05/12/2017
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1013996339
Products in Payments
- OPDIVO (Biological) $245,067
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in West Palm Beach
Mark Gonwa, Md, MD
Diagnostic Radiology — Payments: $1,573
Diagnostic Radiology $1,573
Maria Mata, Md, MD
Diagnostic Radiology — Payments: $21.18
Diagnostic Radiology $21.18
Dr. Teresa Cortinas, M.d, M.D
Diagnostic Radiology — Payments: $14.53
Diagnostic Radiology $14.53
Mrs. Jessica Cohn, Md, MD
Diagnostic Radiology — Payments: $11.10
Diagnostic Radiology $11.10
Dr. Larry Menestrina, Do, DO
Diagnostic Radiology
Diagnostic Radiology
Warren Reuther, Md, MD
Diagnostic Radiology
Diagnostic Radiology